Isonicotinyl hydrazone of rifampicin and isoniazid: Should it be controlled as a related substance (or impurity) in USP monographs for anti-tuberculosis combination products?

Pharmacopeial Forum

Volumn 31, Issue 2, 2005, Pages 646-652

  Mariappan, T T ^a   Singh, Saranjit ^a   Pandey, Rajesh ^b   Sharma, Anshika ^b  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 28844480391     PISSN: 03634655     EISSN: 15421945     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. WHO. Fixed-dose combination tablets for the treatment of tuberculosis. Report of an informal meeting held in Geneva, 27 April 1999. 1999; 14-22.
2. Fox, W. Drug combinations and bioavailability of rifampicin. Tubercle. 1990;71:241-243.
3. Laserson, KF, Kenyon, AS, Kenyon, TA, Layloff T, Binkin NJ. Substandard tuberculosis drugs on the global market and their simple detection. Int J Tuberc Lung Dis. 2001;5:448-454.
4. http://www.who.int/medicines/organization/par/FDC/ FDCmain.shtml (Accessed on 30-07-2004.)
5. Acocella, G. Human bioavailability studies. Bull IUALTD. 1989;64:38-40.
6. Shishoo, CJ, Shah, SA, Rathod, IS, Savale, SS, Vora, MJ. Impaired bioavailability of rifampicin in presence of isoniazid from fixed-dose combination (FDC) formulation. Int J Pharm. 2001;228:53-67.
7. Immanuel, C, Gurumurthy, P, Ramachandran, G, Venkatesan, P, Chandrasekaran, V, Prabhakar, P. Bioavailability of rifampicin following concomitant administration of ethambutol or isoniazid or pyrazinamide or a combination of the three drugs. Indian J Med Res. 2003;118:109-114.
8. http://www.who.int/medicines/organization/par/FDC/Janos_ FDCFPPs Experience_LaingRv1.ppt (Accessed on 30-07-2004.)
9. http://mednet3.who.int/prequal/documents/WHOPreQuali Proj_Nairobi_2.pdf (Accessed on 30-07-2004.)
10. www.uspdqi.org/pubs/other/GHC-DrugQualityMatrix.pdf. (Accessed on 30-07-2004.)
11. Singh, S, Mariappan, TT, Sharda, N, Singh, B. Degradation of rifampicin, isoniazid, and pyrazinamide from prepared mixtures and marketed single and combination products under acid conditions. Pharm Pharmacol Commun. 2000;6:491-494.
12. Sankar, R, Sharda, N, Singh, S. Behavior of decomposition of rifampicin in the presence of isoniazid in the pH range 1-3. Drug Dev Ind Pharm. 2003;29:733-738.
13. Singh, S, Mohan, B. A pilot stability study on anti-tuberculosis four-drug fixed-dose combination products. Int J Tuberc Lung Dis. 2003;7:298-303.
14. Bhutani, H, Mariappan, TT, Singh, S. Physical and chemical instability of anti-TB fixed-dose combination products (FDCs) under accelerated climatic conditions. Int J Tuberc Lung Dis. 2004;8:1073-1080.
15. Singh, S, Mariappan, TT, Sharda, N, Kumar, S, Chakraborti, AK. The reason for an increase in decomposition of rifampicin in the presence of isoniazid under acid conditions. Pharm Pharmacol Commun. 2000;6:405-410.
16. th UNION World Conference on Lung Health. Paris, France, 28 October-1 November 2004.
17. Singh, S, Mariappan, TT, Sankar, R, Sharda, N, Singh B. A critical review of the probable reasons for the poor/variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products and the likely solutions to the problem. Int J. Pharm. 2001;228:5-17.
18. USP 26-NF21. Rockville, MD: United States Pharmacopeial Convention; 2003:1643-1646.
19. http://www.uspdqi.org/pubs/other/ECCMIDPoster2004.pdf (Accessed on 30-07-2004.)
20. Mohan, B, Sharda, N, Singh, S. Evaluation of the recently reported USP gradient HPLC method for analysis of anti-tuberculosis drugs for its ability to resolve degradation products of rifampicin. J Pharm Biomed Anal. 2003;31:607-612.
21. Pandey, R, Khuller, GK. Chemotherapeutic potential of alginate-chitosan microspheres as anti-tubercular drug carriers. J Antimicrob Chemother. 2004;53:635-640.
22. Pandey, R, Zahoor, A, Sharma, S, Khuller, GK. Nanoparticle-encapsulated anti-tubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis. 2003;83:373-378.
23. Carstensen, JT. Kinetic pH profiles. In: Carstensen, JT, Rhodes, CT, Editors. Drug Stability Principles and Practices, 3rd ed. New York: Marcel Dekker, Inc.; 2000:57-111.
24. Maccari, R, Ottana, R, Monforte, F, Vigorita, MG. In vitro antimycobacterial activities of 2′-monosubstituted isonicotinohydrazides and their cyanoborane adducts. Antimicrob Agents Chemother. 2002;46:294-299.
25. www.uspdqi.org/pubs/monographs/rifampin_isoniazi d_ethambutol and_pyrazinamide.pdf (Accessed on 30-07-2004.)
26. Dekker, TG, Lötter, AP. Anti-tuberculosis 4FDC tablets-mystery to chemistry. Int J Tuberc Lung Dis. 2003;7:205-206.
27. Mariappan, TT, Jindal, KC, Singh, S. Overestimation of rifampicin during colorimetric analysis of anti-tuberculosis FDC products containing isoniazid due to formation of isonicotinyl hydrazone. J Pharm Biomed Anal. 2004;36:905-908.
28. Mariappan, TT, Geetha, T, Pandey, R, Jindal, KC, Singh, S. Interference of isonicotinyl hydrazone in the microbiological analysis of rifampicin from anti-tuberculosis FDC products. J Pharm Biomed Anal. 2004;36:643-647.